Gene drives and societal narratives
By Brigitte Nerlich,
Making Science Public
| 08. 21. 2020
A review of nine previous posts about gene drives, most by the same author
Some days ago, I came across an interesting virtual conference (HT @Sarah_A_Hartley) about gene editing which includes a session on ‘societal narratives’. I have written quite a bit about societal narratives of gene editing, but more recently I became involved in the issue of ‘gene drive’, that is, “a system of biased inheritance in which the ability of a genetic element to pass from a parent to its offspring through sexual reproduction is enhanced”. This is a naturally occurring twist in the laws of inheritance that scientists can use (with the help of gene editing) “to develop [artificial] gene-drive modified organisms for public health, conservation, agriculture, and other societal purposes, for example, by suppressing populations of mosquito species that transmit human diseases such as malaria, dengue, Zika, and chikungunya among others” (Gene drives on the horizon, 2016).
I suddenly asked myself: Are there any societal narratives emerging around gene drives? Cloninghas societal narratives, recombinant DNA has societal narratives, genetic engineering has societal narratives (I can’t wait for @matthewcobb’s book about this), genomics has societal narratives, genetic...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...